相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance
Ian D. Ferguson et al.
NATURE COMMUNICATIONS (2022)
Aptamer-Functionalized Micro- and Nanocarriers for Controlled Release
Margarita Vazquez-Gonzalez et al.
ACS APPLIED MATERIALS & INTERFACES (2021)
Facts and Hopes in Multiple Myeloma Immunotherapy
Adam S. Sperling et al.
CLINICAL CANCER RESEARCH (2021)
Surfaceome Proteomic of Glioblastoma Revealed Potential Targets for Immunotherapy
Melanie Rose et al.
FRONTIERS IN IMMUNOLOGY (2021)
Artificial Intelligence in Aptamer-Target Binding Prediction
Zihao Chen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
Nina Shah et al.
LEUKEMIA (2020)
Multiple myeloma: 2020 update on diagnosis, risk-stratification and management
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Aptamers and Antisense Oligonucleotides for Diagnosis and Treatment of Hematological Diseases
Valentina Giudice et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Broad and thematic remodeling of the surfaceome and glycoproteome on isogenic cells transformed with driving proliferative oncogenes
Kevin K. Leung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?
Mayte Sola et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2020)
Resistance Mechanisms towards CD38-Directed Antibody Therapy in Multiple Myeloma
Laurens E. Franssen et al.
JOURNAL OF CLINICAL MEDICINE (2020)
What is the future of immunotherapy in multiple myeloma?
Leo Rasche et al.
BLOOD (2020)
Immune-based therapies in the management of multiple myeloma
Saurabh Zanwar et al.
BLOOD CANCER JOURNAL (2020)
Surfaceome nanoscale organization and extracellular interaction networks
Damaris Bausch-Fluck et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2019)
Targeting transcription factors in multiple myeloma: evolving therapeutic strategies
Shirong Li et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Inside the Black Box: What Makes SELEX Better?
Natalia Komarova et al.
MOLECULES (2019)
Potential and Challenges of Aptamers as Specific Carriers of Therapeutic Oligonucleotides for Precision Medicine in Cancer
Silvia Nuzzo et al.
CANCERS (2019)
An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery
Silvia Catuogno et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2019)
Targeting transcription factors in cancer - from undruggable to reality
John H. Bushweller
NATURE REVIEWS CANCER (2019)
Aptamers: Uptake mechanisms and intracellular applications
Sorah Yoon et al.
ADVANCED DRUG DELIVERY REVIEWS (2018)
Screening and characterization of an Annexin A2 binding aptamer that inhibits the proliferation of myeloma cells
Weihua Zhou et al.
BIOCHIMIE (2018)
Targeting Transcription Factors for Cancer Treatment
Melanie Lambert et al.
MOLECULES (2018)
Aptamer-Mediated Delivery and Cell-Targeting Aptamers: Room for Improvement
Amy C. Yan et al.
NUCLEIC ACID THERAPEUTICS (2018)
Current Advances in Aptamers for Cancer Diagnosis and Therapy
Shin-ichiro Hori et al.
CANCERS (2018)
Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies
Shuanghui Yang et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2018)
Targeting c-met receptor tyrosine kinase by the DNA aptamer SL1 as a potential novel therapeutic option for myeloma
Yibin Zhang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
The in silico human surfaceome
Damaris Bausch-Fluck et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Aptamer Chimeras for Therapeutic Delivery: The Challenging Perspectives
Carla Lucia Esposito et al.
GENES (2018)
Aptamer-iRNAs as Therapeutics for Cancer Treatment
Mario M. Soldevilla et al.
PHARMACEUTICALS (2018)
CD38 antibodies in multiple myeloma: back to the future
Niels W. C. J. van de Donk et al.
BLOOD (2018)
Aptamers as targeted therapeutics: current potential and challenges
Jiehua Zhou et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Suppression of FOXM1 Transcriptional Activities via a Single-Stranded DNA Aptamer Generated by SELEX
Qin Xiang et al.
SCIENTIFIC REPORTS (2017)
CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma
Johannes M. Waldschmidt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
A unique aptamer-drug conjugate for targeted therapy of multiple myeloma
J. Wen et al.
LEUKEMIA (2016)
A combined microRNA-based targeted therapeutic approach to eradicate glioblastoma stem-like cells
Carla L. Esposito et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Anti-Transcription Factor RNA Aptamers as Potential Therapeutics
Estefania Mondragon et al.
NUCLEIC ACID THERAPEUTICS (2016)
High throughput sequencing analysis of RNA libraries reveals the influences of initial library and PCR methods on SELEX efficiency
Mayumi Takahashi et al.
SCIENTIFIC REPORTS (2016)
Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer therapeutics
Axel Vater et al.
DRUG DISCOVERY TODAY (2015)
Selective delivery of therapeutic single strand antimiRs by aptamer-based conjugates
Silvia Catuogno et al.
JOURNAL OF CONTROLLED RELEASE (2015)
The Effects of SELEX Conditions on the Resultant Aptamer Pools in the Selection of Aptamers Binding to Bacterial Cells
Camille L. A. Hamula et al.
JOURNAL OF MOLECULAR EVOLUTION (2015)
DNA Aptamers in the Diagnosis and Treatment of Human Diseases
Qinchang Zhu et al.
MOLECULES (2015)
The isolation of an RNA aptamer targeting to p53 protein with single amino acid mutation
Liang Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization
Julia Hoellenriegel et al.
BLOOD (2014)
A DNA aptamer to c-Met inhibits cancer cell migration
R. Ueki et al.
CHEMICAL COMMUNICATIONS (2014)
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
S. K. Kumar et al.
LEUKEMIA (2014)
Inhibiting Heat Shock Factor 1 in Human Cancer Cells with a Potent RNA Aptamer
H. Hans Salamanca et al.
PLOS ONE (2014)
Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma
Francis Robert et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy
Aldo M. Roccaro et al.
CELL REPORTS (2014)
Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer® Olaptesed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma
Heinz Ludwig et al.
BLOOD (2014)
Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment
Sonia D'Souza et al.
BLOOD (2012)
Clinical and prognostic role of annexinA2 in multiple myeloma
Anja Seckinger et al.
BLOOD (2012)
Bi-specific Aptamers Mediating Tumor Cell Lysis
Achim Boltz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay
Fernando Pastor et al.
NATURE (2010)
Characterization of RNA aptamers that disrupt the RUNX1-CBFβ/DNA complex
Jenny L. Barton et al.
NUCLEIC ACIDS RESEARCH (2009)
Selection and characterization of anti-NF-kappa B p65 RNA aptamers
Susan E. Wurster et al.
RNA (2008)
RNA aptamers to initiation factor 4A helicase hinder cap-dependent translation by blocking ATP hydrolysis
A Oguro et al.
RNA (2003)
Yeast genetic selections to optimize RNA decoys for transcription factor NF-κB
LA Cassiday et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
分享论文
